Neha Vapiwala, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: September 27, 2005
Jan 9, 2014 - For patients with previously untreated chronic lymphocytic leukemia and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy is associated with improved outcomes, according to a study published online Jan. 8 in the New England Journal of Medicine.
Feb 2, 2011
May 20, 2013